Everything below concerns LC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
increased price due to cost-intensive production; sensitivity to moisture (tablets can degrade at higher humidity); poor physical resistance (easy to break); limited ability to incorporate higher concentrations of active drug.
=== Ornithine decarboxylase === Ornithine decarboxylase (ODC), is a labile protein that is the first rate-limiting enzyme in polyamine biosynthesis. Its degradation is regulated by antizyme that is induced by polyamine production. NQO1 has been shown to stabilize the degradation of ODC by binding to it and protecting it from 20S proteasomal degradation.
== Function == Vitamin D-binding protein belongs to the albumin gene family, together with human serum albumin and alpha-fetoprotein. It is a multifunctional protein found in plasma, ascitic fluid, cerebrospinal fluid (CSF), and on the surface of many cell types. It binds to various forms of vitamin D, including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), the 25-hydroxylated forms (calcifediol), and the active hormonal product, 1,25-dihydroxyvitamin D (calcitriol). The major proportion of vitamin D in blood is bound to this protein. Once bound, it transports vitamin D and its plasma metabolites between the skin, liver, and kidney, and then on to the various target tissues. The expression of GC, and therefore the production of GC Vitamin D binding protein, is restricted towards the liver; in an RNA-sequence (RNA-seq) study of tissues samples from 95 human individuals across 27 tissue representations analysed on December 19, 2024, GC was expressed primarily in the tissue of the liver, at a mean RPKM (reads per kilobase million) value of 1258.79 ± 214.721 across 3 samples. In comparison, the next highest RPKM means were in the anatomically nearby gallbladder, at a value of 235.12 ± 73.639 across 3 samples, followed by the stomach, at a value of 23.974 ± 19.053 across 3 samples, the duodenum, at a value of 22.508 ± 6.514 across 2 samples, and the kidney, at a value of 12.033 ± 12.168 across 4 samples. Other tissue samples held a negligible value in comparison to the liver, gallbladder, stomach, duodenum, and kidney.
== Motive == The prosecution said that McTavish had been inspired by an episode of the detective series A Man Called Ironside, in which a character said that insulin was untraceable as a murder weapon and proceeded to murder a person using this method. McTavish had notably discussed with colleagues how the programme had taught her that soluble insulin would be an untraceable agent for homicide.
Sources: en.wikipedia.org
4-maleylacetoacetate is a homodimer. It is classified as an isomerase transferase. It has a total residue count of 216 and a total atom count of 1700. This enzyme's theoretical weight is 24.11 KDa. 4-maleylacetoacetate isomerase has 3 isoforms The most common isoform has two domains, the N-terminal domain (4-87) the C terminal domain (92-212) and the glutathione binding site (14-19, 71-72 and 115-117). The N-terminal domain has a four stranded beta sheet which is sandwiched by alpha helices on both sides to form a three layer sandwich tertiary structure. The C terminal domain is composed mostly of alpha helices and has an up down structure of tightly bundled alpha helices. Glutathione binds in positions 14-19, 71-72, and 115-117. It also binds the sulfate ion and dithiothreitol.
=== Animals === Proteases are used throughout an organism for various metabolic processes. Acid proteases secreted into the stomach (such as pepsin) and serine proteases present in the duodenum (trypsin and chymotrypsin) enable the digestion of protein in food. Proteases present in blood serum (thrombin, plasmin, Hageman factor, etc.) play an important role in blood-clotting, as well as lysis of the clots, and the correct action of the immune system. Other proteases are present in leukocytes (elastase, cathepsin G) and play several different roles in metabolic control. Some snake venoms are also proteases, such as pit viper haemotoxin, which interferes with the victim's blood clotting cascade. Proteases determine the lifetime of other proteins playing important physiological roles like hormones, antibodies, or other enzymes. This is one of the fastest "switching on" and "switching off" regulatory mechanisms in the physiology of an organism. By a complex cooperative action, proteases can catalyze cascade reactions, which result in rapid and efficient amplification of an organism's response to a physiological signal.
Elena Galoppini, Italian chemist and professor at Rutgers University–Newark whose research focuses on the development of redox- and photo-active molecules to modify surfaces. Juliet Gerrard, New Zealand chemist and Prime Minister's Chief Science Advisor in the administration of Jacinda Ardern. Clare Grey, British chemist pioneering the use of nuclear magnetic resonance spectroscopy to study battery technology. Awarded the Körber European Science Prize in 2021. Professor at the University of Cambridge. Paula T. Hammond, American chemical engineer focusing on macromolecular design and synthesis of materials for drug delivery systems, particularly in relation to cancer, immunology, and immunotherapy. Professor at MIT. Jeanne Hardy, American biophysicist and chemical biologist. Known for her work in the design of allosteric binding sites and control elements into human proteases. Professor at the University of Massachusetts. Geraldine Harriman, American Organic Chemist. Developed Firsocostat. Chief Scientific Officer and co-founder of HotSpot. Rachel Haurwitz, American biochemist and structural biologist. Her work regards CRISPR based technologies, she is a cofounder of Caribou Biosciences, a genome editing and cell therapy development company. Kim Eunkyoung, South Korean materials chemist known for her work in electrochromic (EC) materials design Katja Loos, German polymer chemist working on the design, synthesis, and characterisation of novel and sustainable polymeric materials and macromolecules. Chair of the board of the Zernike Institute for Advanced Materials.
== More on GRK7 == GRK7 is a member of the family of G protein-coupled receptor kinases, and is officially named G protein-coupled receptor kinase 7. GRK7 is found primarily in mammalian retinal cone cells, where it phosphorylates light-activated photopsins, members of the family of G protein-coupled receptors that recognize light of various wavelengths (red, green, blue). Phosphorylated, light-activated photopsin binds to the cone arrestin protein arrestin-4 to terminate the light-activated signaling cascade. The related GRK1, also known as rhodopsin kinase, serves a similar function in retinal rod cells subserving dim light black-and-white peripheral vision outside the fovea. The post-translational modification of GRK7 by geranylgeranylation and α-carboxyl methylation is important for regulating the ability of the enzyme to recognize color opsins in cone outer segment disk membranes. Arrestin-1 bound to rhodopsin in retinal rods prevents rhodopsin activation of the transducin protein to turn off photo-transduction completely. While cone visual transduction is much less well characterized, it is expected that arrestin-4 bound to GRK7-phosphorylated color photopsin prevents opsin activation of the transducin protein to turn off photo-transduction completely.
== Gut microbiota == The gut microbiota of T. molitor consists of many different bacterial species present at low abundance. A study found a predominance of genus Spiroplasma species in the phylum Tenericutes in the gut samples of T. molitor, but there was variation found in the community composition between individuals. Although some Spiroplasma species are known insect pathogens, the T. molitor larvae did not experience any harmful effects from the presence of the Spiroplasma in the gut, indicating that they are not pathogens to the host. By comparing this to the bacterial communities found in other insects, it was found that the Spiroplasma species found were specific to T. molitor. The gut bacteria community structure was not significantly affected by the presence of antibiotics or by the exposure of the beetle larvae to a more highly diverse soil bacteria community. There is a negative relationship between bacterial diversity and ampicillin concentration, meaning ampicillin treatment caused a reduction in the bacterial community size, which was determined with pyrosequencing of the 16S rRNA gene, and no negative relationship when kanamycin was added. Polystyrene foam decreases T. molitor fecundity, but the beetle can fully develop using the plastic as its primary source of food, which makes it an interesting alternative to recycle polystyrene. However, when the mealworm's microbiota is disrupted by an antibiotic treatment, it loses its ability to digest polystyrene, suggesting that its associated gut microbes are essential in the digestion process.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.